Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor
Open Access
- 14 August 2018
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 7 (9) , 4744-4754
Abstract
NUCOLL43 is a novel ovarian clear cell carcinoma (O‐CCC) cell line that arose from a primary culture of a patient's malignant ascites. The cells grow reliably in cell culture with a doubling time of approx. 45 hours and form colonies at high efficiency. They have a very high degree of loss of heterozygosity (LOH) affecting approximately 85% of the genome, mostly copy neutral and almost identical to the original tumor. The cells express epithelial (pan‐cytokeratin) and mesenchymal (vimentin) characteristics, CA125 and p16, like the original tumor. They also express ARID1A but not HNF‐1β and, like the original tumor, and are negative for p53 expression, with no evidence of p53 function. NUCOLL43 cells express all other DNA damage response proteins investigated and have functional homologous recombination DNA repair. They are insensitive to cisplatin, the PARP inhibitor rucaparib, and MDM2 inhibitors but are sensitive to camptothecin, paclitaxel, and NVP‐BEZ235. The NUCOLL43 cell line represents a distinct subtype of O‐CCC that is p53 and HNF‐1β null but expresses ARID1A. Its high degree of similarity with the original tumor genomically and proteomically, as well as the high level of LOH, make this an interesting cell line for O‐CCC research. It has been deposited with Ximbio.Keywords
Funding Information
- JGW Patterson Foundation (30015 088.033/PA/)
- Medical Research Council (MR/N017838/1)
- Wellcome Trust (206723/Z/17/Z)
- Newcastle University
This publication has 38 references indexed in Scilit:
- Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA geneHuman Cell, 2013
- Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in TaiwanJournal of Gynecologic Oncology, 2013
- The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in MiceMolecular Cancer Therapeutics, 2011
- p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumorsOncogene, 2011
- Analysis of Epithelial and Mesenchymal Markers in Ovarian Cancer Reveals Phenotypic Heterogeneity and PlasticityPLOS ONE, 2011
- Morphologic Spectrum of Immunohistochemically Characterized Clear Cell Carcinoma of the OvaryAmerican Journal of Surgical Pathology, 2011
- Trypsin-induced proteome alteration during cell subculture in mammalian cellsJournal of Biomedical Science, 2010
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying TheoryAmerican Journal of Surgical Pathology, 2010
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- Genome-Wide Loss of Heterozygosity and Uniparental Disomy in BRCA1/2-Associated Ovarian CarcinomasClinical Cancer Research, 2008